What it's for (Indications)
- Anastrozole is a potent and highly selective non-steroidal aromatase inhibitor primarily indicated for the treatment of breast cancer in postmenopausal women.
- Specific indications include the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, offering a critical therapeutic option to reduce recurrence risk by significantly lowering circulating estrogen levels.
- Furthermore, it is approved as first-line treatment for postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer, providing a foundational endocrine therapy.
- Anastrozole also serves as a valuable second-line therapy for advanced breast cancer in postmenopausal women who have experienced disease progression following prior tamoxifen therapy, demonstrating its versatility across different stages of the disease progression.
- This drug plays a crucial role in endocrine therapy strategies by effectively lowering estrogen levels, thereby inhibiting the growth of estrogen-dependent tumors.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of anastrozole is 1 mg administered orally once daily, without regard to meals. This consistent daily regimen is crucial for maintaining stable drug concentrations and ensuring optimal therapeutic efficacy in managing hormone receptor-positive breast cancer. Adherence to this prescribed dosage is paramount, and patients should be advised against missing doses or altering the frequency without consulting their healthcare provider. For patients with mild-to-moderate hepatic impairment or mild-to-moderate renal impairment, no dose adjustment is generally required. However, caution is advised for patients with severe hepatic impairment or severe renal impairment, and their treatment should be managed by a physician based on careful clinical assessment and individualized patient factors to optimize safety and efficacy. |
Safety & Warnings
Common Side Effects
- Patients receiving anastrozole may experience a range of side effects, with some being more common than others.
- Frequently reported adverse reactions include hot flashes, asthenia (weakness or lack of energy), arthralgia (joint pain), and peripheral edema, which are often attributable to the profound estrogen deprivation.
- Other common side effects encompass nausea, vomiting, headache, vaginal dryness, mood disturbances including depression, and hair thinning.
- More serious, though less common, adverse effects require vigilant monitoring.
- These include an increased risk of osteopenia and osteoporosis, potentially leading to bone fractures due to significant estrogen suppression.
- There is also a noted risk of hypercholesterolemia and, in some cases, cardiovascular events such as ischemic heart disease.
- Liver enzyme elevations have been observed, necessitating periodic liver function monitoring.
- Patients should be thoroughly counseled on these potential effects and instructed to report any persistent or severe symptoms to their healthcare professional.
Serious Warnings
- Black Box Warning: Anastrozole (Arimidex) does not carry an FDA-mandated Black Box Warning. However, it is crucial to recognize several 'Serious Warnings' that necessitate careful patient management and ongoing monitoring due to the potential for significant adverse health outcomes. These include the substantial risk of decreased bone mineral density leading to osteoporosis and an increased incidence of bone fractures. Healthcare providers should assess baseline bone health and implement strategies to mitigate this risk, such as bone density scans, calcium/vitamin D supplementation, or bisphosphonate therapy. Additionally, anastrozole has been associated with an increased risk of cardiovascular events, including ischemic heart disease, requiring vigilant monitoring of patients, especially those with pre-existing cardiovascular risk factors like hypertension, hyperlipidemia, or diabetes. Patients should be thoroughly educated on these risks and encouraged to report any concerning symptoms promptly to their healthcare professional for timely intervention and management, ensuring optimal safety during treatment.
- Anastrozole therapy requires careful consideration of several important warnings to ensure patient safety and optimize treatment outcomes.
- A significant concern is the potential for decreased bone mineral density and an increased risk of fractures due to the profound suppression of estrogen, which plays a vital role in bone health.
- Baseline and periodic monitoring of bone mineral density using DEXA scans is highly recommended, and interventions like calcium and vitamin D supplementation or bisphosphonate therapy may be necessary.
- Anastrozole has also been associated with an increased risk of cardiovascular events, including ischemic heart disease, necessitating careful monitoring of patients with pre-existing cardiovascular risk factors.
- Elevated cholesterol levels have been observed, warranting lipid profile monitoring.
- The drug is contraindicated in premenopausal women and during pregnancy due to its mechanism of action and potential for fetal harm.
- Caution is advised in patients with severe hepatic or renal impairment, and specific monitoring protocols may be needed.
How it Works (Mechanism of Action)
Anastrozole functions as a potent and highly selective non-steroidal aromatase inhibitor. Its primary mechanism of action involves the competitive inhibition of the aromatase enzyme, which is responsible for the conversion of adrenal androgens (such as androstenedione and testosterone) into estrogens (estrone and estradiol, respectively) in peripheral tissues, including adipose tissue, muscle, and breast cancer cells. In postmenopausal women, where the ovaries no longer produce significant amounts of estrogen, this peripheral conversion by aromatase becomes the primary source of circulating estrogens. By effectively blocking this enzyme, anastrozole significantly lowers serum estrogen levels, including estradiol, estrone, and estrone sulfate, to very low or undetectable concentrations. This profound estrogen deprivation effectively inhibits the growth and progression of hormone-sensitive breast cancer cells, which rely on estrogen for proliferation, thus providing a critical therapeutic benefit in endocrine-responsive tumors.
Commercial Brands (Alternatives)
No other brands found for this formula.